“…Drug-delivery systems (DDSs) can be used to reduce the side effects, provide controlled release, and selectively target cancer-related diseases. − Metal–organic frameworks (MOFs) have become promising candidates as DDSs due to their well-defined structures, tunable pore size, high surface area, high loading/release of guest compounds, amphiphilic internal microenvironment, and pH-dependent degradation under simulated physiological conditions. − For example, the organic ligand 1,1′-biphenyl-4,4′-dicarboxylic acid (BPDC) has produced various porous frameworks: UiO-67 (Zr), UiO-67-(NH 2 ) 2 (Zr), bio-MOF-1 (Zn), and BPDC-Zr. ,,− These materials have been employed as carriers for the intracellular delivery of chemotherapeutic agents such as pemetrexed, 5-fluorouracil (5-FU), and Ru-90, and other pharmaceutical compounds such as brimonidine, calcein, and α-cyano-4-hydroxycinnamic acid. ,,− Specifically, 5-FU (∼6 wt %) and pemetrexed (∼18 wt %) were simultaneously loaded into UiO-67-(NH 2 ) 2 ; this MOF showed a pH-dependent release of both drugs in simulated physiological buffers . In addition, commercial BPs were employed recently to generate ALEN-, ZOLE-, and RISE-based coordination complexes and demonstrated suitable pH-dependent degradation, bone affinity [e.g., nano -Ca@ZOLE to hydroxyapatite (HA), 36%, 1 day], and cytotoxicity [e.g., nano -Ca@ALEN, relative cell viability (%RCV) = 38 ± 1% at 7.5 μM in 72 h] against the MDA-MB-231 cell line. − However, these BP-based coordination complexes did not lead to porous materials able to encapsulate guest molecules. − Furthermore, the reaction of benzene-1,4-bis(bisphosphonic acid) (BBPA), the BP analogue of benzene-1,4-dicarboxylic acid (BDC), coordinated with Ca 2+ successfully led to BBPA-Ca form I, a 3D framework with channels (7 × 12 Å) large enough to encapsulate and release 5-FU (∼30 wt %) .…”